Briefing
Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients.
The RaDaR tumor-informed assay was used to measure ctDNA over time in 276 prospectively collected samples from people with high-risk melanoma.
- Design: Evidence level 3
- Assay: RaDaR